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Tackground: Endovascular application of pulmonary heart valves has been recently
ntroduced clinically. A tissue-engineering approach was pursued to overcome the
urrent limitations of bovine jugular vein valves (degeneration and limited longev-
ty). However, deployment of the delicate tissue-engineered valves resulted in
evere tissue damage. Therefore the objective of this study was to prevent tissue
amage during the folding and deployment maneuver.
aterial and Methods: Porcine pulmonary heart valves, small intestinal submucosa,
nd ovine carotid arteries were obtained from a slaughterhouse. After dissection and
ntimicrobial incubation, the valves were trimmed (removal of sinus and most of the
uscular ring) to fit into the deployment catheter. The inside (in-stent group, n 
) or outside (out-stent group, n  6) of a nitinol stent was covered by an acellular
mall intestinal submucosa, and the valves were sutured into the stent. The valves
ere folded, tested for placement in the deployment catheter, and decellularized
nzymatically. Myofibroblasts were obtained from carotid artery segments and
eeded onto the scaffolds. The seeded constructs were placed in a dynamic biore-
ctor system and cultured for 16 consecutive days. After endothelial cell seeding,
he constructs were folded, deployed, and processed for histology and surface
lectron microscopy.
esults: The valves opened and closed competently throughout the entire dynamic
ulture. Surface electron microscopy revealed an almost completely preserved tissue
n the in-stent group. Stents covered with small intestinal submucosa on the outside,
owever, showed severe damage.
onclusion: This study demonstrates that small intestinal submucosa covering of the
nside of a pulmonary valved stent can prevent stent strut–related tissue damage.
ulmonary valve regurgitation with late right ventricular dysfunction after
repair of tetralogy of Fallot is a well-known entity. Current treatment options
include right ventricular outflow tract (RVOT) reconstruction by means of
ither valved conduit surgery1 or percutaneous endovascular valve implantation2
ven so, the latter concept represents a tremendous benefit for the patients because
t avoids a redo operation; the currently used bovine jugular vein valves are
lutaraldehyde-fixed xenogeneic heart valves likely to be prone to degeneration and
ill eventually require reinterventions. Tissue engineering might offer a potential
athway to overcome the present limitations of heart valve substitutes in ge3
issue-engineered valves will have unique characteristics of viability and ability to
row and remodel. Preliminary results, however, revealed that the folding and
eployment maneuver of the extremely fragile and delicate tissue-engineered valves
esulted in severe cell abrasion (Stock et al, unpublished data, 2005). Because this
amage is caused by the stent struts itself, the objective of this study was to develop
strategy to prevent tissue damage during the folding and deployment maneuver byhielding the valve from the stent struts.
he Journal of Thoracic and Cardiovascular Surgery ● Volume 131, Number 6 1323
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ETaterials and Methods
he general approach to cell isolation, culture, and seeding, as well
he basic decellularization procedure, was described in detail pre-
iously4; however, several modifications were required and -
lied. This study conformed to the “Guide for the care and use of
aboratory animals” published by the US National Institutes of
ealth (publication no. 85-23, revised 1996).
ell and Tissue-culture Medium
tandard cell and tissue-culture medium was Dulbecco’s modified
agle’s medium (Invitrogen, Carlsbad, Calif) supplemented with 10%
etal calf serum (Biochrom AG, Berlin, Germany), 1% penicillin-
treptomycin (PS; 10,000 U/10 mg/mL, Invitrogen), and 1.5 g/
00 mL recombinant human fibroblast growth factor, basic (Pro-
ega GmbH, Mannheim, Germany).
ell Isolation and Culture
ix- to 9-cm-long segments of ovine carotid arteries were obtained
rom approximately 6-month-old slaughterhouse lambs by using a
lean surgical technique. The arteries were stored in Dulbecco’s
odified Eagle’s medium with fetal calf serum and PS at 4°C and
rocessed within 60 minutes. Endothelial cells (ECs) were ob-
ained by means of a collagenase instillation technique for 20
inutes at 37°C and 5% CO2 (0.2% collagenase type A [Roche
iagnostics GmbH, Mannheim, Germany] in phosphate-buffered
aline [PBS; Invitrogen]) and cultured in 0.1% gelatin-precoated
gelatine type A; Sigma-Aldrich Chemie GmbH, Munich, Ger-
any) tissue-culture flasks (BD Falcon; BD Biosciences, San Jose,
alif). The remaining vessel wall segments were minced into
-mm2 pieces, distributed on Petri dishes (Nunc GmbH, Wie-
en, Germany) and cultured in cell-culture medium. After migra-
ion of the myofibroblasts (MFs) on the culture dishes (5-9 days
fter harvest), cells were cultured in gelatin-precoated flasks. Both
ell populations were incubated at 37°C and 5% CO2 and serially
assaged with trypsin–ethylenediamine tetraacetic acid (EDTA) in
anks’ buffered saline solution (Invitrogen). Approximately 28 
days were needed to obtain 15 confluent T75 tissue-culture
asks.
issue Harvest
earts and small intestines of pigs (90-120 kg weight) were
btained under clean conditions from a local slaughterhouse within
5 minutes of slaughter and immediately transferred in Hanks’
uffered saline solution (Biochrom AG) to the laboratory. Pulmo-
ary valves were excised and freed of adherent fat and most of the
Abbreviations and Acronyms
EC  endothelial cell
EDTA ethylenediamine tetraacetic acid
MF myofibroblast
PBS  phosphate-buffered saline
PS  penicillin-streptomycin
RVOT right ventricular outflow tract
SIS  small intestinal submucosayocardium, leaving only a thin ridge of subvalvular muscle tissue F
324 The Journal of Thoracic and Cardiovascular Surgery ● Junnd the pulmonary artery (Figure 1). Six porcine pulmonary v
ere dissected to match the size of the stent and the valve for each
tented valve. The valve diameter was determined with a Hegar
izer before sinus removal and muscular trimming. Valves with a
iameter of 24 mm were chosen for implantation into the 24-mm
tent. Segments of porcine small intestine (approximately 20 cm in
ength) were cleaned by thoroughly washing with PBS (Invitro-
en), followed by incubation in povidone-iodine solution (Mun-
ipharma, Limburg, Germany) solution for 15 minutes. Decon-
aminated segments were repeatedly washed with PBS, and the
ucosa and any connective tissue were removed mechanically5-7
he remaining small intestinal submucosa (SIS) was transferred
nto PBS containing an antibiotic solution (1.2 mg of amikacin, 3
g of flucytosin, 1.2 mg of vancomycin, 0.3 mg of ciprofloxacin,
nd 1.2 mg of metronidazol in 1 mL of aqua ad inject) and stored
t 4°C for 48 hours.
tent Characteristics and Design
adially self-expanding nitinol stents (Nitinol Devices & Compo-
ents Inc, Fremont, Calif) were used in the present study. The
ires are soft and highly malleable, molding 2 ranks of 14 rhombs
ach. Bare stents were 28 mm in length and 24 mm in diameter
hen fully expanded at 37°C.
The stent is sterilized in 98% alcohol for 60 minutes with
ubsequent PBS washing and dried overnight with UV light in a
aminar flow box.
alved Stent Construction
he inside (in-stent group, n  6) or outside (out-stent group, n 
) of a nitinol stent was covered with an acellular porcine SIS, and
he valves were sutured into the covered stent with interrupted 7-0
onofilament sutures (Prolene; Ethicon, Norderstedt, Germany;
igure 1. Scalloped pulmonary heart valve, leaving only the com-
issures and leaflets.igure 2).
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ETecellularization Procedure
he entire construct (stent with SIS and implanted valve) was
ashed for 30 minutes at room temperature in povidone-iodine
olution and sterile PBS, followed by another overnight incu-
ation at 4°C in an antibiotic solution (1.2 mg of amikacin, 3
g of flucytosin, 1.2 mg of vancomycin, 0.3 mg of ciprofloxa-
in, and 1.2 mg of metronidazol in 1 mL aqua ad inject). After
his decontamination procedure, the valves were placed in a
olution of 0.05% trypsin and 0.02% EDTA (Biochrom AG) at
7°C and 5% CO2 for 12 hours during continuous 3-dimensional
haking. After removal of the trypsin-EDTA, the constructs were
ashed with PBS for another 24 hours to remove residual cell
etritus. The decellularized matrices were immediately processed
or subsequent cell seeding.
eseeding and Dynamic Culture Procedure
fter cell expansion to a total quantity of approximately 3 
07 cells, MFs were trypsinized, resuspended in culture me-
ium, and seeded onto the decellularized pulmonary valves in a
equential seeding process that involved 2 days of static seeding
n the inner and outer surface. Subsequently, the valves were
Figure 2. A, Out-stent construct with SIS surrounding t
stent struts. B, In-stent construct with SIS located in blaced in a pulsatile flow system (bioreactor, Figure 3) andh
The Journal of Thoracicxposed to defined physical signals with a fixed frequency (1
z) and pressure conditions (3 L/min and 60/40 mm Hg) over
time period of 16 days. A final coating with ECs (9  106
ells) for 2 days under static conditions, which allows the cells
o form sediment on the valve wall and the leaflets, completed
he reseeding. The entire culture period was conducted in a
tandard incubator at 37°C and 5% CO2. PS supplement (5 mL)
as added every 4 days.
olding and Deployment Maneuver
eeded and cultured valved stents were manually folded and
nserted into a 22F modified commercially available catheter.
olding was achieved by means of uniform pressure application
f the thumb and index, middle, and ring fingers of both hands.
fter a learning curve, all valves in this study were folded and
ushed into the deployment catheter in one step by one inves-
igator (D.I.). After 5 minutes of folding, the valved stent was
eployed in vitro. They were placed back in the bioreactor and
ested for competent opening and closing by using PBS. Imme-
iately afterward, they were analyzed macroscopically and
ent, resulting in a direct contact of the valve with the
een the nitinol stent and the scalloped valve.he st
etwistologically.
and Cardiovascular Surgery ● Volume 131, Number 6 1325
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EThenotypic Cell Identification by Means of
mmunocytochemistry
Cs were identified by the presence of Factor VIII–related antigen
von Willebrand factor; DAKO Cytomation GmbH, Hamburg,
ermany). MFs were characterized by means of incubation with
onoclonal mouse antibodies for -smooth muscle actin (Sigma),
esmin (DAKO), vimentin (DAKO), and fibronectin (DAKO).
iochemical Assays
iochemical assays were performed for analysis of cellular and ex-
racellular components of native and decellularized porcine heart
alves. For this purpose, an additional 8 valve leaflets for each assay
ere used. All samples were normalized according to equivalent dry
eight. A DC Protein-Assay (Bio-Rad, Hercules, Calif) was used to
etect the total protein concentration. Total DNA was isolated and
urified by means of sequential organic extractions with phenol (Roth,
arlsruhe, Germany) and phenol-chloroform-isoamyl alcohol (Roth)
nd quantified by means of spectrophotometry (Helios ; Spectronic
nicam, Cambridge, United Kingdom). Cell proliferation was ascer-
ained with a CellTiter Non-Radioactive Cell Proliferation Assay
Promega) and measured with the 96-well plate enzyme-linked im-
unosorbent assay reader “Sunrise” (TECAN, Crailsheim, Germany)
or metabolic activity. Tissue was completely acid digested to mea-
ure the total 4-hydroxyproline content. After tissue extraction, total
ollagen, elastin, and glycosaminoglycan levels were quantified by
sing SIRCOL, FASTIN, and BLYSCAN assays (Biocolor, Belfast,
orthern Ireland).8
istology
ach heart valve was carefully removed from the stent, and the 3
eaflets were separated. One leaflet was processed for histology.
pecimens were fixed for 72 hours at 20°C in 4% paraformalde-
yde in 0.1 mol/L cacodylate buffer, pH 7.4. They were washed in
ap water for 2 hours, dehydrated in graded alcohol, and finally
mbedded in paraffin (Merck, Darmstadt, Germany). Sections (5-8
m) of each tissue sample were deparaffinized and rehydrated. For
eneral morphology, serial sections were stained with hematoxylin-
osin stain (cellular components and nuclei). For identification of
Cs on the tissue surface, Factor VIII–related antigen staining was
Figure 3. Stented heart valves in the bioreactor syste
opened (C) positions.onducted. The slides were thoroughly rinsed, with repeated turn- m
326 The Journal of Thoracic and Cardiovascular Surgery ● Junng of the slide during staining, to avoid edge-effect artifacts.
ections were analyzed and documented by using common bright-
eld light microscopy (Axiovert S 100; Zeiss, Jena, Germany).
nvironmental Surface Electron Microscopy
he remaining 2 leaflet specimens for environmental surface elec-
ron microscopy were fixed in 4% paraformaldehyde for 24 hours.
ixed specimens were dehydrated in an alcohol gradient (40%,
0%, 80%, and 99.9% for 10 minutes each). Samples were critical
oint dried by using a critical point drier (CPD030; BAL-TEC,
alzers, Liechtenstein) and mounted on stubs for surface electron
icroscopy. Mounted samples were subsequently coated with gold
y using a sputter coating device SCD005 (BAL-TEC). Samples
ere analyzed with a scanning electron microscope (LEO-1450
P; LEO, Oberkochen, Germany).
tatistical Analysis
ll results are presented as mean values  standard deviations
95% confidence intervals). The 2-sided t test was used to assess
ifferences between the heart valve tissues. Statistical analysis was
onducted with the software package SPSS for windows, version
0.0 (SPSS GmbH Software, München, Germany).
esults
solated ECs and MFs
he confluent ECs displayed a cobblestone morphology of
attened cells with large rounded nuclei and demonstrated
trong granular perinuclear immunofluorescence for von
illebrand factor (data not shown). Immunocytochemistry
f isolated and fixed carotid artery medial cells revealed a
trong expression of -smooth muscle actin, vimentin, and
bronectin, which proved the MF phenotype, according to
revious publications.4,9
ecellularized Matrix
istologic analysis of the decellularized valve tissue sec-
ions stained with hematoxylin and eosin showed that treat-
ith the valve in the closed (A), intermediate (B), andm went with trypsin-EDTA for 12 hours followed by a 24-
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ET
our washing with PBS converted native porcine pulmonary
alves in a cell-free scaffold (Figure 4, A). A Russel-Mova
entachrome stain visualized the physiologic valve structure
onsisting of arterialis, fibrosa, spongiosa, and ventricularis,
ith no apparent disruptions of the leaflet histoarchitecture
Figure 4, B). DNA and proliferation assays show
mounts of cells and cell debris (41.06 5.5 vs 6.83 2.31
g/mg dry tissue; 95% confidence interval, 29.65 respective
8.79; P  .05), corresponding to an 84% reduction of
ellular components (each n  8). As confirmed by means
f histology, the remaining DNA does not resemble intact
ells but rather cell debris. Assays for quantification of
xtracellular matrix demonstrated a good preservation of the
igure 4. Hematoxylin-eosin (A) and 4=,6-diamidino-Z-phenylin-
ole (B) staining reveal the ingrowth of ovine myofibroblasts into
he valve leaflets, resulting in a tissue comparable with a native
ulmonary heart valve in both groups. (Original magnification
00.)ajor structural components (collagen, elastin, and glycos- a
The Journal of Thoracicminoglycans; Figure 5). The detected minor increase
ollagen and elastin after the decellularization process is an
lready described phenomen10 caused by the use of tryps
DTA, inducing an enhanced collagen and elastin extrac-
ion effect on the matrix.
acroscopic Appearance of Constructs After
eployment
he hydrodynamic pulsatile flow system enabled synchro-
ous opening and closing of the leaflets throughout the
ntire culture period in all tissue-engineered stent valves.
fter folding and deployment, the valves were placed in the
ioreactor. By using PBS medium, they were tested for
ompetent opening and closing. Gross appearance showed
ntact and pliable constructs.
istology and Immunohistochemistry of Reseeded
alves
ematoxylin-eosin staining revealed a confluent ingrowth
f ovine MFs into the valve leaflets, revealing a picture
omparable with that of native tissue in both groups (F
). From a recent study, we know that this ingrow
niform from the inflow and outflow side of the valve
eaflets.4 Surface characteristics differed significantly. In t
ut-stent group almost no surface standing cells were iden-
ified. In the in-stent group contrast-flattened cells, resem-
ling ECs, covered the leaflet structures (Figure 7, A).
mmunohistochemistry with Factor VIII–related antigen
onfirmed this observation (Figure 7, B).
nvironmental Surface Electron Microscopy
amples (n  3) of valve leaflets after in vitro culture and
efore and after folding and deployment were compared.
he pretreatment group revealed a smooth surface without
ell and tissue disruption (Figure 8, A). The in-stent grou
howed a similar appearance with minimal injury (Figur
). In contrast, the out-stent group had severe tissue dam-
igure 5. Effect of decellularization on cellular and extracellular
atrix components.ge, with matrix disruption and deep lesions (Figure 8, C).
and Cardiovascular Surgery ● Volume 131, Number 6 1327
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ET
iscussion
ight ventricular dysfunction caused by severe pulmonary
alve regurgitation is a serious complication after transan-
ular patch augmentation of the RVOT for treatment of
etralogy of Fallot.11 Up to 5 years ago, the treatment
hoice was a redo operation with reconstruction of the
VOT with a valved conduit.12 After extensive in viv
valuation,13 Bonhoeffer and colleagues14 introduced the
oncept of endovascular pulmonary valve application clin-
cally. Because of the limited diameter of the vascular
ccess, they used low-profile, glutaraldehyde-fixed bovine
ugular vein valves. However, these valves, like all biologic
alves, are likely prone to degeneration and calcification
igure 6. Hematoxylin-eosin staining reveals the ingrowth of
vine myofibroblasts into the valve leaflets, resulting in a tissue
omparable with a native pulmonary heart valve in both groups.
Original magnification 200.)nd have a limited long-term function. A recent publication f
328 The Journal of Thoracic and Cardiovascular Surgery ● Junf Ruiz and associates15 investigated the use of acellular S
o create a low-profile heart valve for transcatheter place-
ent by using a guided tissue regeneration approach.
uided tissue regeneration differs from tissue engineering
y using acellular matrices that ought to be repopulated
fter implantation by the adjacent host tissue.16 Although
he results of Ruiz and associates15 indicate degradation o
he SIS with some kind of remodeling by means of tissue
eoformation, it is unlikely that the obtained results can be
ransferred to human subjects.17,18 Accordingly, we believ
hat preimplantation seeding by means of tissue engineering
emains a prerequisite. In a recent publication the complete
epopulation of a decellularized porcine pulmonary heart
alve with ovine vascular wall cells was demonstrat4
omplete pulmonary roots will require large deployment
atheters (24F). Because these will potentially jeopardize
he access vessel (femoral vein), we decided to reduce the
alve dimensions by removing the sinus and the majority of
he muscular annulus. Placement of the now scalloped heart
alve leaflets in a stent alone will, however, have only a
ery small attachment area in the patient’s pulmonary root,
nd paravalvular leakage is very likely to occur. A wrapping
uff with SIS was applied to prevent these leaks and facil-
tate cell seeding (in a scalloped valve the cell suspension
ill rinse off immediately). We have now shown that the
ocation of the SIS wrap is crucial to prevent injuries of the
itinol struts during folding and deployment. Only if the SIS
s implanted between the stent and the scalloped valve
eaflets (outflow surface) can it protect the valve leaflets
rom device-related trauma. A remaining limitation is the
igure 7. Immunohistochemistry with Factor VIII–related antigen
onfirmed the identity of the flattened surface–located cells as
ndothelial cells. (Original magnification 400.)act that the deployment catheter consists of on outer sheath
e 2006
av
l
c
s
o
r
r the
R
d
i
a
b
d
i of
p
f n
o
i
t
f
t
t
f
b
t
d
w
i
u
a
u
h
f
l
c
s
C
I
s
v
c
f
r
F
t
s
s
t
r
Stock et al Evolving Technology
ETnd a central mandrill. This mandrill passes through the
alve and causes trauma to the inflow area of the valve
eaflets. This is a mechanism well known from transvalvular
atheter procedures. We believe that the endothelial abra-
ions require further in-depth studies, with particular focus
n in vivo studies.
From clinical experience, the RVOT in patients after
epair of tetralogy of Fallot is normally not tube like but
ather funnel like.11 Proximal anchoring of the stent in 
VOT is crucial because migration will result in valvular
ysfunction. New stents are currently under testing to offer
ndividually customized stent solutions for patients.19,20 The
pplied SIS is very compliant and can be easily modeled to
asically all stent designs.
A variety of limitations remain to be addressed. In ad-
ition to the evaluation of the optimal cell source for seed-
ng of the constructs,9 the potential immunologic barrier 
orcine extracellular matrix tissue in human subjects needs
urther clarification.21 An important and crucial limitatio
f midterm to long-term tissue engineering in general is an
mmanent infection risk. Despite the use of antibiotics in the
issue-culture medium, we observed bacterial or fungal in-
ections during the initial 16 days of valve culture in more
han 50% of the cases. All attempts to conduct long-term
esting (24 hours) after the final deployment maneuver
ailed because of bacterial or fungal infections (n  9). We
elieve that this can be attributed to 2 circumstances. First,
he repeated manipulation (implantation in the bioreactor,
ynamic culture, EC seeding, removal from the bioreactor
ith subsequent folding, and deployment and repeated test-
ng in the bioreactor) bears an infection risk. Second, the
sed porcine hearts and SIS, as well as the ovine carotid
rtery segments, were obtained from a local slaughterhouse
nder “clean” conditions. Sole use of sterilely obtained
earts, SIS, and arteries for in vitro testing was turned down
rom our local animal ethics committee. To overcome this
imitation, we are currently testing the tissue-engineered
onstructs in the pulmonary valve position of growing
heep.
onclusion
n the present study we demonstrated for the first time the
uccessful merging of 2 novel technologies: endovascular
alve application and tissue engineering. Furthermore, the
ritical issue of device-related tissue damage during valve
olding and deployment was successfully addressed. The
esulting necessity of in vivo testing is currently being
igure 8. Environmental surface electron microscopy. A, The con-
rol group (native ovine pulmonary valve) revealed a smooth
urface without cell and tissue disruption. B, The in-stent groupuption and deep lesions.howed a similar appearance with minimal injury. C, In contrast,
he out-stent group had severe tissue damage, with matrix dis-
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ETddressed in a study using the engineered heart valve con-
tructs in the pulmonary roots of juvenile sheep.
eferences
1. de Ruijter FT, Weenink I, Hitchcock FJ, Meijboom EJ, Bennink GB.
Right ventricular dysfunction and pulmonary valve replacement after
correction of tetralogy of Fallot. Ann Thorac Surg. 2002;73:1794-800.
2. Coats L, Tsang V, Khambadkone S, van Doorn C, et al. The potential
impact of percutaneous pulmonary valve stent implantation on right
ventricular outflow tract re-intervention. Eur J Cardiothorac Surg.
2005;27:536-43.
3. Nerem RM. Cellular engineering. Ann Biomed Eng. 1991;19:529-45.
4. Schenke-Layland K, Opitz F, Gross M, et al. Complete dynamic
repopulation of decellularized heart valves by application of defined
physical signals—an in vitro study. Cardiovasc Res. 2003;60:497-509.
5. Hodde JP, Record RD, Tullius RS, Badylak SF. Retention of endo-
thelial cell adherence to porcine-derived extracellular matrix after
disinfection and sterilization. Tissue Eng. 2002;8:225-34.
6. Shell DH 4th, Croce MA, Cagiannos C, et al. Comparison of small-
intestinal submucosa and expanded polytetrafluoroethylene as a vas-
cular conduit in the presence of gram-positive contamination. Ann
Surg. 2005;241:995-1001.
7. White JK, Agnihotri AK, Titus JS, Torchiana DF. A stentless trileaflet
valve from a sheet of decellularized porcine small intestinal submu-
cosa. Ann Thorac Surg. 2005;80:704-7.
8. Stock UA, Wiederschain D, Kilroy SM, et al. Dynamics of extracel-
lular matrix production and turnover in tissue engineered cardiovas-
cular structures. J Cell Biochem. 2001;81:220-8.
9. Schenke-Layland K, Riemann I, Opitz F, et al. Comparative study of
cellular and extracellular matrix composition of native and tissue
engineered heart valves. Matrix Biol. 2004;23:113-25.
0. Schenke-Layland K, Vasilevski O, Opitz F, et al. Impact of decellu-
larization of xenogeneic tissue on extracellular matrix integrity for
tissue engineering of heart valves. J Struct Biol. 2003;143:201-8.
330 The Journal of Thoracic and Cardiovascular Surgery ● Jun1. Frigiola A, Redington AN, Cullen S, Vogel M. Pulmonary regurgita-
tion is an important determinant of right ventricular contractile dys-
function in patients with surgically repaired tetralogy of Fallot. Cir-
culation. 2004;110(suppl):II153-7.
2. Mayer JE Jr. Uses of homograft conduits for right ventricle to pulmo-
nary artery connections in the neonatal period. Semin Thorac Cardio-
vasc Surg. 1995;7:130-2.
3. Bonhoeffer P, Boudjemline Y, Saliba Z, et al. Transcatheter implan-
tation of a bovine valve in pulmonary position. Circulation. 2000;102:
813-6.
4. Bonhoeffer P, Boudjemline Y, Saliba Z, et al. Percutaneous replace-
ment of pulmonary valve in a right-ventricle to pulmonary-artery
prosthetic conduit with valve dysfunction. Lancet. 2000;356:1403-5.
5. Ruiz CE, Iemura M, Medie S, et al. Transcatheter placement of a
low-profile biodegradable pulmonary valve made of small intestinal
submucosa: a long-term study in a swine model. J Thorac Cardiovasc
Surg. 2005;130:477-84.
6. Stock UA, Schenke-Layland K. Performance of decellularized xeno-
geneic tissue in heart valve replacement. Biomaterials. 2006;27:1-2.
7. Simon P, Kasimir MT, Seebacher G, et al. Early failure of the tissue
engineered porcine heart valve SYNERGRAFT in pediatric patients.
Eur J Cardiothorac Surg. 2003;23:1002-6.
8. Goldstein S, Clarke DR, Walsh SP, et al. transpecies heart valve
transplant: advanced studies of a bioengineered xeno-autograft. Ann
Thorac Surg. 2000;70:1962-9.
9. Migliavacca F, Schievano S, Dubini G, et al. Percutaneous valve
replacement: an engineer’s perspective. Presented at: Advances in
Tissue Engineering and Biology of Heart Valves Meeting; Florence,
Italy; Sept 15-18, 2004.
0. Lutter G, Kuklinski D, Berg G, et al. Percutaneous aortic valve
replacement: an experimental study. I. studies on implantation. J Tho-
rac Cardiovasc Surg. 2002;123:768-76.
1. Rieder E, Seebacher G, Kasimir MT, et al. Tissue engineering of heart
valves: decellularized porcine and human valve scaffolds differ im-
portantly in residual potential to attract monocytic cells. Circulation.
2005;111:2792-7.
e 2006
